Literature DB >> 9112136

Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana.

S Harder1, S Rietbrock.   

Abstract

On the basis of a publication by Cochetto et al. [1981] we performed simulations of the effect-time course (high-rating) after smoking marijuana. The intention was to characterize the concentration-effect relationship of THC and to provide information on how long psychotropic effects (and therefore impairment of cognitive or motoric functions) last after intake of a cannabinoid product. The parameter estimates (+/-SD) of the pharmacokinetic disposition and the pharmacodynamic model (sigmoidal Emax model) after smoking 1 marijuana cigarette containing 9 mg THC were as follows: T/2 alpha = 5 minutes (+/-1.2), T/2 beta = 75 minutes (+/-23), Teq (equilibrium half-life with the effect site) = 29 minutes. (+/-2), ECe50 = 7.2 ng/ml THC (+/-0.5), E0 (baseline high rating) = 18% (+/-2.0), Emax (amplitude of the high rating) = 23% (+/-2.5), Hill coefficient = 9.0 (+/-3.0). On the basis of this curve fit, the effect-time course after repeated smoking (5 joints) in different intervals (120, 60, and 30 minutes) and for different dose strengths 9 mg (standard joint), 3 mg (weak joint) and 1 mg (agricultural hemp) were simulated. The duration of the effect after 1 dose of 9 mg is about 45 minutes. After the last cigarette, recovery (decline < 50% Emax) will last about 100 minutes. A dosing interval of 1 h leads to a continuous "high", and recovery will last about 150 minutes after the last joint. Smoking the weak dose strength (3 mg) every hour will result in a short plateau of the maximal effect (about 20 minutes) and a decline after the last joint within 1 h. Only repeated smoking every 30 minutes will lead to a prolonged plateau phase with a recovery time of about 80 minutes. Using hemp with a low THC content (1 mg), dosing intervals of 2 h and 1 h will not provoke a psychotropic response due to THC. Smoking every 30 minutes will probably lead to a short-term moderate response. In conclusion, our simulations show that dose and dosing interval are determinants of the duration of the psychotropic effects of THC. These simulations may be beneficial for the interpretation of THC levels, e.g. associated with accidents or traffic violations. Furthermore, misuse of natural hemp with a low THC content seems unlikely.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9112136

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  12 in total

Review 1.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

2.  A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

Authors:  Barth Wilsey; Thomas Marcotte; Alexander Tsodikov; Jeanna Millman; Heather Bentley; Ben Gouaux; Scott Fishman
Journal:  J Pain       Date:  2008-04-10       Impact factor: 5.820

3.  Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.

Authors:  Jules A A C Heuberger; Zheng Guan; Olubukayo-Opeyemi Oyetayo; Linda Klumpers; Paul D Morrison; Tim L Beumer; Joop M A van Gerven; Adam F Cohen; Jan Freijer
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

Review 4.  Self-administration of cannabinoids by experimental animals and human marijuana smokers.

Authors:  Zuzana Justinova; Steven R Goldberg; Stephen J Heishman; Gianluigi Tanda
Journal:  Pharmacol Biochem Behav       Date:  2005-06       Impact factor: 3.533

5.  Identification of a high-affinity binding site involved in the transport of endocannabinoids.

Authors:  S A Moore; G G Nomikos; A K Dickason-Chesterfield; D A Schober; J M Schaus; B-P Ying; Y-C Xu; L Phebus; R M A Simmons; D Li; S Iyengar; C C Felder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-28       Impact factor: 11.205

Review 6.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling.

Authors:  Zheng Liu; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2018-06-07       Impact factor: 4.335

8.  Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial.

Authors:  Ronald J Ellis; Will Toperoff; Florin Vaida; Geoffrey van den Brande; James Gonzales; Ben Gouaux; Heather Bentley; J Hampton Atkinson
Journal:  Neuropsychopharmacology       Date:  2008-08-06       Impact factor: 7.853

9.  How Harmonious and Obsessive Passion for Alcohol and Marijuana Relate to Consumption and Negative Consequences.

Authors:  Mai-Ly N Steers; Clayton Neighbors; M Christina Hove; Nichole Olson; Christine M Lee
Journal:  J Stud Alcohol Drugs       Date:  2015-09       Impact factor: 2.582

10.  Weed or wheel! FMRI, behavioural, and toxicological investigations of how cannabis smoking affects skills necessary for driving.

Authors:  Giovanni Battistella; Eleonora Fornari; Aurélien Thomas; Jean-Frédéric Mall; Haithem Chtioui; Monique Appenzeller; Jean-Marie Annoni; Bernard Favrat; Philippe Maeder; Christian Giroud
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.